13 hours ago
1
Zorica Nastasic/E+ via Getty Images
- OKYO Pharma (NASDAQ:OKYO) shared positive results from a recent mid-stage study that tested Urcosimod for treating nerve-related eye pain.
- After 12 weeks of treatment, 75% of patients who followed the study guidelines and received 0.05% Urcosimod experienced more than an 80% decrease in their
English (US) ·